Komorbidität bei rheumatoider Arthritis

Albrecht, Katinka

doi:10.1055/s-0034-1370262

Cited by 4 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Comorbidities in RA are associated with inflammatory activity, disease-related organ damage or medication [ 1 ]. They may be present before the onset of RA, develop during the course of the disease, associated with RA or iatrogenically induced [ 2 ]. Osteoporosis is a very common comorbidity in RA [ 3 ].…”

Section: Introductionmentioning

confidence: 99%

Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007–2017

et al. 2020

View full text Add to dashboard Cite

Osteoporosis is a frequent comorbidity in rheumatoid arthritis (RA). Due to the improved treatment options for RA, we expect a long-term decrease in osteoporosis as an accompanying disease. Data from the German National Database (NDB) were used to investigate whether the frequency of osteoporosis has changed in the last 10 years. From 2007 to 2017, approximately 4000 patients were documented annually with data on therapy and comorbidity. The cross-sectional data were summarised descriptively. Age, sex, disease duration, disease activity and glucocorticoids were considered as influencing factors. The Cochrane-Armitage test for trend was used to test whether the frequency of osteoporosis at the first visit changed from 2007 to 2017. Osteoporosis frequency in RA patients (mean age 63 years, 75% female) decreased from 20% in 2007 to 6% in 2017 (p < 0.001). The decrease affected women (22% to 17%) and men (14% to 8%) in all age groups and both short-term (≤ 2-year disease duration: 9% to 3%) and long-term RA patients (> 10-year disease duration: 28% to 20%). Patients with high disease activity and patients who took glucocorticoids (GC) were more often affected by osteoporosis than patients in remission or without GC. Drug prophylaxis in patients without osteoporosis increased (20% to 41% without GC, 48% to 55% with GC). Men with GC received less prophylactic treatment than women (48% vs. 57% in 2017). In this cohort, osteoporosis in patients with RA is less frequently observed compared to former years. RA-specific risk factors for osteoporosis such as disease activity and GC therapy have declined but long-term GC use is still present. Assessment of osteoporosis in RA patients should be investigated more consistently by bone density measurement. Male RA patients still need to be given greater consideration regarding osteoporosis drug prophylaxis, especially when GC therapy is needed.

show abstract

Section: Introductionmentioning

confidence: 99%

Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007–2017

et al. 2020

View full text Add to dashboard Cite

show abstract

“…However, considering the rather low proportions of dispensed drugs especially in patients with severe levels of pain and/or depressive symptoms, an overestimation of treatment because of misclassification seems to be of less importance. With respect to the spectrum of drugs dispensed, we further had no information regarding co‐morbidities such as renal insufficiency, which limit therapeutic options and thus probably influenced drug choice.…”

Section: Discussionmentioning

confidence: 99%

Pain, depressive symptoms and medication in German patients with rheumatoid arthritis—results from the linking patient‐reported outcomes with claims data for health services research in rheumatology (PROCLAIR) study

Jobski

Ramos

Albrecht

et al. 2017

Pharmacoepidemiology and Drug

View full text Add to dashboard Cite

show abstract

“…[ 2 ] Although, RA is a burdensome disease for most of the patients, comorbidities usually provide additional disadvantageous contribution to RA course. [ 3 ]…”

Section: Introductionmentioning

confidence: 99%

Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity

et al. 2018

View full text Add to dashboard Cite

The objective of this study was to assess the frequency of comorbidities and multimorbidities in rheumatoid arthritis (RA) patients under biologic therapy and their effects on biological disease modifying antirheumatic drugs (DMARDs) choice, timing, and response.Hacettepe University Biologic Registry (HUR-BIO) is single center biological DMARD registry. Cardiovascular, infectious, cancer, and other comorbidities were recorded with face to face interviews. Multimorbidity is defined as >1 comorbidity. Disease duration, initial date of biological DMARDs, initial and overall biological DMARD choice were recorded. Disease activity score-28 (DAS-28) responses were compared to comorbidity presence and multimorbidity.Total of 998 RA patients were enrolled into the study. The mean age was 53.1 (12.5) and mean disease duration (standard deviation [SD]) was 11.7 (7.5) years. At least 1 comorbidity was detected in 689 (69.1%) patients, 375 (37.9%) patients had multimorbidity. Patients had mean 1.36 ± 1.32 comorbidity. The median durations of first biological DMARDs prescription were 60 (3–552) months after RA diagnosis. For multimorbidity patients, the median first biological prescription duration was longer than the duration for patients without multimorbidity (72 [3–552] vs 60 [3–396] months, P < .001). The physicians prescribe tumor necrosis factor inhibitor (TNFi) biological drugs less frequently than other biological DMARDs in patients with at least 1 comorbidity (66.2% vs 74.5%, P = .007) or multimorbidity (34.6% vs 43.5%, P = .006). Patients with comorbidities and multimorbidity achieved DAS-28 remission less frequently than patients without comorbidity (31.6% vs 42.6%, P = .012 and 27.2% vs 39.7%, P = .001, respectively).In real life, physicians may postpone to prescribe biological DMARDs and less frequently choose TNFi biological drugs in patients with multimorbidity. Furthermore, comorbidity may have a negative effect on the treatment response.

show abstract

Komorbidität bei rheumatoider Arthritis

Cited by 4 publications

References 24 publications

Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007–2017

Osteoporosis in patients with rheumatoid arthritis: trends in the German National Database 2007–2017

Pain, depressive symptoms and medication in German patients with rheumatoid arthritis—results from the linking patient‐reported outcomes with claims data for health services research in rheumatology (PROCLAIR) study

Starting of biological disease modifying antirheumatic drugs may be postponed in rheumatoid arthritis patients with multimorbidity

Contact Info

Product

Resources

About